Dr Curigliano chairs this closing session at the 'Coming of age for CDK 4/6 inhibitors' symposium at ESMO 2016.
He reaffirms the key take-home messages for breast oncologists and support professionals in this interactive question and answer session.
Supported by a grant from Pfizer Inc.